GeoVax Labs Company Insiders
| GOVXW Stock | USD 0.06 0 5.94% |
GeoVax Labs employs about 17 people. The company is managed by 11 executives with a total tenure of roughly 40 years, averaging almost 3.0 years of service per executive, having 1.55 employees per reported executive. Recap of GeoVax Labs' management performance can provide insight into the venture performance.
GeoVax |
GeoVax Labs Management Team Effectiveness
The company has return on total asset (ROA) of (1.121) % which means that it has lost $1.121 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.7602) %, meaning that it generated substantial loss on money invested by shareholders. GeoVax Labs' management efficiency ratios could be used to measure how well GeoVax Labs manages its routine affairs as well as how well it operates its assets and liabilities.GeoVax Labs Workforce Comparison
GeoVax Labs is one of the top stocks in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 53.0. GeoVax Labs totals roughly 17.0 in number of employees claiming about 32% of equities under Health Care industry.
GeoVax Labs Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific GeoVax Labs insiders, such as employees or executives, is commonly permitted as long as it does not rely on GeoVax Labs' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, GeoVax Labs insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Spencer John N Jr over two weeks ago Acquisition by Spencer John N Jr of 30000 shares of GeoVax Labs at 0.11 subject to Rule 16b-3 | ||
Mcnally Robert T over three weeks ago Acquisition by Mcnally Robert T of 53925 shares of GeoVax Labs at 5.0 subject to Rule 16b-3 | ||
Chase Randal D over a month ago Acquisition by Chase Randal D of 26400 shares of GeoVax Labs at 0.15 subject to Rule 16b-3 | ||
Reynolds Mark over a month ago Acquisition by Reynolds Mark of 60184 shares of GeoVax Labs at 5.0 subject to Rule 16b-3 | ||
Chase Randal D over three months ago Acquisition by Chase Randal D of 16613 shares of GeoVax Labs at 5.0 subject to Rule 16b-3 | ||
Mcnally Robert T over three months ago Acquisition by Mcnally Robert T of 50000 shares of GeoVax Labs at 0.755 subject to Rule 16b-3 | ||
Reynolds Mark over a year ago Acquisition by Reynolds Mark of 10000 shares of GeoVax Labs at 0.17 subject to Rule 16b-3 |
GeoVax Labs Notable Stakeholders
A GeoVax Labs stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as GeoVax Labs often face trade-offs trying to please all of them. GeoVax Labs' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting GeoVax Labs' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| David Dodd | President Chairman | Profile | |
| Mark CPA | CFO Secretary | Profile | |
| MD FACOG | Special Directors | Profile | |
| CPA CPA | CFO Sec | Profile | |
| Mark Newman | Chief Officer | Profile | |
| Jeffrey Welch | Head Operations | Profile | |
| Harriet Robinson | Chief Founder | Profile | |
| John Sharkey | Vice Development | Profile | |
| Thomas OBrien | Vice Compliance | Profile | |
| John Niles | Head Operations | Profile | |
| McKee MD | Chief Officer | Profile |
About GeoVax Labs Management Performance
The success or failure of an entity such as GeoVax Labs often depends on how effective the management is. GeoVax Labs management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of GeoVax management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the GeoVax management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform in the United States and internationally. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia. Geovax Labs is traded on NASDAQ Exchange in the United States.
Please note, the imprecision that can be found in GeoVax Labs' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of GeoVax Labs. Check GeoVax Labs' Beneish M Score to see the likelihood of GeoVax Labs' management manipulating its earnings.
GeoVax Labs Workforce Analysis
Traditionally, organizations such as GeoVax Labs use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare GeoVax Labs within its industry.GeoVax Labs Manpower Efficiency
Return on GeoVax Labs Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.5M | |
| Net Loss Per Executive | 2.4M | |
| Working Capital Per Employee | 256.8K | |
| Working Capital Per Executive | 396.9K |
Additional Tools for GeoVax Stock Analysis
When running GeoVax Labs' price analysis, check to measure GeoVax Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeoVax Labs is operating at the current time. Most of GeoVax Labs' value examination focuses on studying past and present price action to predict the probability of GeoVax Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeoVax Labs' price. Additionally, you may evaluate how the addition of GeoVax Labs to your portfolios can decrease your overall portfolio volatility.